Advanced search
Start date

Implications of adaptive immune response modulation in cancer control

Grant number: 21/06058-7
Support Opportunities:Regular Research Grants
Duration: November 01, 2021 - October 31, 2023
Field of knowledge:Health Sciences - Medicine
Principal Investigator:Pedro Otavio de Campos Lima
Grantee:Pedro Otavio de Campos Lima
Host Institution: Centro Infantil de Investigações Hematológicas Dr Domingos A Boldrini (CIB). Campinas , SP, Brazil
Associated researchers:José Andrés Yunes


The immune system has the ability to recognize damage-associated molecular patterns (DAMPs) generated by tumor growth, which can lead to its elimination or continued inflammation. The initial innate immune response sets the stage for a specific adaptive immune reaction that is equipped to eradicate the neoplastic lesion, and often happens long before the disease becomes clinically detectable. When antitumor immunosurveillance fails, the resulting tumors frequently contain immune cells that tend to acquire a hypofunctional phenotype characterized by anergy and exhaustion. The object of our proposal is the study of tumor-infiltrating T lymphocytes and, more precisely, the test of an immunomodulatory approach that has the potential to restore the lymphocyte antitumor function. For this purpose, we will use syngeneic murine models of solid tumor and leukemia in which we will try to revert the state of hyperactivation and hypofunctionality of lymphocytes, in order to control the neoplastic growth. Lymphocytes will be isolated from the tumors of animals that receive or not the immune modulation protocol; thereafter, the cells will be phenotypically examined by flow cytometry for the expression of surface markers of anergy, exhaustion and hyperactivation, as well as for proliferative capacity. This characterization will be completed by determining the metabolic profile, susceptibility to apoptosis, and diversity of the T cell receptor repertoire of infiltrating lymphocytes. The effector function of lymphocytes recovered from the lesions will be determined in vitro in tests of cytolytic activity against tumor targets, and the ability to secrete pro and/or anti-inflammatory cytokines will be measured by ELISA/ELISPOT. The immunotherapeutic potential of this approach will ultimately be evaluated through tumor progression and animal survival curves in the syngeneic models. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items

Please report errors in scientific publications list by writing to: